Nature Reviews Cancer contents February 2016 Volume 16 Number 2 pp67-126

If you are unable to see the message below, click here to view.

Advertisement
Nature Immunology Inside View: huNOG-EXL Mouse    Nature recently spoke with molecular biologist Michael P. Seiler PhD, Taconic's Associate Director of Product Management, Immune System Models and GEMS Design, about a new strain, the huNOG-EXL, its application and the promise these human immune system mice hold for scientific advancement and drug discovery.   Download Your Copy Now!
TABLE OF CONTENTS
February 2016 Volume 16 Number 2		Advertisement
Impact Factor 37.4 *	In this issue Research Highlights Review Analysis Perspectives Also this month  Featured article: The kinome 'at large' in cancer Emmy D. G. Fleuren, Luxi Zhang, Jianmin Wu & Roger J. Daly	An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation.  Now open for submissions
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Pancreatic cancer: Spotlight on B cells p67 | doi:10.1038/nrc.2016.7 Three papers published in Cancer Discovery show that B cells have diverse contributions to pancreatic tumorigenesis. PDF Cancer risk: Debating the odds p68 | doi:10.1038/nrc.2016.5 An analysis by Tomasetti and Vogelstein prompted considerable debate about the origins of the genetic mutations that drive tumour initiation. Further fuel to this debate has recently been provided by an analysis from Wu et al. PDF Tumorigenesis: Tracking early tumour cells p69 | doi:10.1038/nrc.2015.20 Nguyen, Pellacani et al. report data suggesting that a slow multi-step evolutionary process might not be required to generate mammary tumours following KRAS-G12D expression, and that KRAS-G12D-expressing tumours can rapidly accumulate heterogeneous clones. PDF Resistance: Crizotinib makes a comeback p69 | doi:10.1038/nrc.2016.6 A new study reports how tracking the evolution of resistance in serial biopsies revealed the molecular mechanisms by which a patient with metastatic non-small-cell lung cancer became resensitized to crizotinib. PDF Metabolism: Totally addicted to NAD+ p70 | doi:10.1038/nrc.2015.19 A study in Cancer Cell reports that the growth of some isocitrate dehydrogenase 1 (IDH1)-mutant cancers is dependent on their addiction to NAD+, a metabolic vulnerability that can be targeted by drugs that are already in clinical trials. PDF IN BRIEF Therapy: Targeting replication fork stalling | Tumorigenesis: Pathway to stemness | Tumour microenvironment: Obesity promotes prostate cancer invasion | Tumour suppression: p53 suppresses retrotransposition PDF Cancer JOBS of the week Faculty Position in Cancer Biology Fox Chase Cancer Center Postdoctoral Position – Cancer Immunotherapy (In Vivo Research) German Cancer Research Center (DKFZ). Post Doctoral Scientist Yr 1-3- RI Childhood Cancer Nationwide Children's Hospital Research Fellow in Molecular Cancer Pathogenesis (Functional Genomics and Proteomics) Memorial Sloan Kettering Cancer Center (MSK) Assistant Professor Faculty Positions in Cancer Genetics Beth Israel Deaconess Medical Center - Harvard Medical School More Science jobs from Cancer EVENT Molecular Pathology and Diagnosis of Cancer 09.10.16 Hinxton, UK More science events from
REVIEW		Top
A panoply of errors: polymerase proofreading domain mutations in cancer Emily Rayner, Inge C. van Gool, Claire Palles, Stephen E. Kearsey, Tjalling Bosse, Ian Tomlinson & David N. Church p71 | doi:10.1038/nrc.2015.12 Recent studies have shown that germline and somatic mutations in the proofreading exonuclease domains of the replicative DNA polymerases Pol δ and Pol ε are associated with several cancers. This Review summarizes what these mutations are and how they might drive tumorigenesis, and highlights their potential as novel biomarkers and therapeutic targets. Abstract | Full Text | PDF
ANALYSIS		Top
The kinome 'at large' in cancer Emmy D. G. Fleuren, Luxi Zhang, Jianmin Wu & Roger J. Daly p83 | doi:10.1038/nrc.2015.18 This Analysis article discusses characterization of the kinome in human cancers through genomic, proteomic and functional genomic analyses. In particular, it presents an analysis of cancer genomic data to derive a new census of protein kinase cancer drivers. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
TIMELINE Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies Alex R. D. Delbridge, Stephanie Grabow, Andreas Strasser & David L. Vaux p99 | doi:10.1038/nrc.2015.17 Research on the BCL-2-regulated apoptotic pathway has led to the development of small molecules called BH3-mimetics that bind to pro-survival BCL-2 proteins to induce apoptosis of malignant cells. This Timeline article describes the history of research on the BCL-2 family of proteins and their roles in cancer. Abstract | Full Text | PDF
OPINION BRCAness revisited Christopher J. Lord & Alan Ashworth p110 | doi:10.1038/nrc.2015.21 The development of therapeutic approaches that target BRCA-mutant tumours has led to the possibility of expanding the range of patients who may benefit from such strategies. Tumours with 'BRCAness', a similar phenotype to germline BRCA-mutant tumours, are increasingly being identified, and this Opinion article discusses the advances and challenges in this context. Abstract | Full Text | PDF | Supplementary information
VIEWPOINT Acquired resistance to immunotherapy and future challenges Nicholas P. Restifo, Mark J. Smyth & Alexandra Snyder p121 | doi:10.1038/nrc.2016.2 Many patients have now received various types of immunotherapy, so we asked three scientists to give their views on whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2014 Journal Citation Report (Thomson Reuters, 2015)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.